Category Archives: Uncategorized

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment

Posted by Weill Cornell Breast Center in Uncategorized

Dr. Linda Vahdat is seeking men and women with HER2+ metastatic breast cancer to participate in a research study.

The purpose of this study is to evaluate the effectiveness of margetuximab in combination with standard of care chemotherapies in the setting of patients with metastatic HER2+ breast cancer who have received prior treatment with trastuzumab, pertuzumab, and adotrastuzumab.

To see learn more and see if you qualify to participate [go]

Copper depletion may reduce breast cancer relapse in patients at high risk

Posted by Weill Cornell Breast Center in Uncategorized

Dr. Linda Vahdat speaks with MDLinx about copper depletion research in triple negative breast cancer.

“Copper is an interesting element. It’s involved in multiple biologic processes, which are important for tumor progression both within the tumor itself and within the tumor microenvironment. In the tumor microenvironment, it facilitates tumors doing their bad things,” explained lead author Linda T. Vahdat, MD, MBA, professor of medicine, Weill Cornell Medicine and NewYork-Presbyterian, and director of the Breast Cancer Research Program and co-leader of the Breast Cancer Program, Meyer Cancer Center, New York, NY.

To learn more and see the original article and interview video [go]

Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination with Pembrolizumab in Subjects With Metastatic Triple Negative Breast Cancer

Posted by Weill Cornell Breast Center in breast cancer, breast cancer subtypes, Clinical Trials, Triple Negative Breast Cancer, Uncategorized and tagged with , , , ,

Dr. Linda Vahdat is seeking volunteers for a new research study in triple negative breast cancer.

This clinical trial is for women with metastatic triple-negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.

The purpose of this study is to evaluate the effectiveness and safety of eribulin mesylate (“eribulin”) in combination with pembrolizumab in metastatic (spread of cancer from one part of body to another) triple-negative breast cancer.

For more information visit our website

You can also find us on Twitter and Facebook

Dr. Linda Vahdat on Gelmbatumumab Vedotin as a Treatment in Triple Negative Breast Cancer

Posted by Weill Cornell Breast Center in breast cancer, Breast Cancer News, breast cancer subtypes, Clinical Trials, Conferences, Triple Negative Breast Cancer, Uncategorized
“With antibody drug conjugates, generally speaking is that you can deliver a much higher dose of drug to the tumor than you normally would be able to. The hope is that if you can deliver the drug to the tumor that you can kill more cancer cells.” – Linda Vahdat, M.D. 
Linda Vahdat, MD, professor of Medicine, director of the Breast Cancer Research Program, chief of the Solid Tumor Service, Weill Cornell Medical, discusses the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB. Vahdat says the purpose of the drug conjugate is to target gpNMB, also known as osteoactivan, which is important for cell migration and invasion.

Vahdat says the hope among oncologists for glembatumumab vedotin is that the treatment can deliver a much higher dose of drug to the tumor than you normally would be able to, and directly into the tumor cell.